Key events, in time order
None yet
None yet
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
Talphera makes injectable drugs for hospital settings, like a freeze-dried anticoagulant for heart-lung machines and pre-filled syringes of blood-pressure stabilizers. Think of it as a specialty pharmacy building niche products for monitored medical environmen
No revenue yet—the company is pre-commercial, burning about USD 0.01B to 0.02B annually on R&D and operations. Money comes only from future product sales, which haven't started.
No visible moat: Talphera's pipeline faces direct competition from established players like Pfizer and Fresenius in anticoagulants and vasopressors, with no approved product or proprietary advantage yet.
